Outrun Therapeutics is a preclinical biotechnology company focused on harnessing the therapeutic potential of protein stabilization through E3 ligase inhibition. Their proprietary platform enables the development of small molecule inhibitors that target E3 ligases, which play a crucial role in the regulation of protein stability within cells. By inhibiting specific E3 ligases, Outrun aims to restore the natural disease suppression processes of the body, particularly in the context of hard-to-treat solid tumors and other diseases. This innovative approach seeks to maintain the levels of critical proteins that are often destabilized in various conditions, thereby addressing significant challenges in therapeutic development.

The company’s lead program is centered on a small molecule inhibitor designed to target an E3 ligase that destabilizes a tumor suppressor protein, showcasing their commitment to tackling complex cancer types. Outrun's platform not only facilitates the identification of novel E3 ligase targets but also enhances the specificity and selectivity of their inhibitors, which is essential for minimizing side effects and improving treatment outcomes. With a strong foundation in E3 ligase biology and a robust discovery platform, Outrun Therapeutics is positioned to advance the field of protein stabilization and develop first-in-class therapies across multiple disease areas, including oncology and neurology.

United Kingdom

Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.

Outrun TX

Company Details